In 812 patients with untreated metastatic TNBC, adding capivasertib to paclitaxel did not improve median OS vs placebo (17.7 vs 18.0 months; HR 0.92) or in PIK3CA/AKT1/PTEN-altered tumours (HR 1.05). PFS numerically favoured it; grade 3+ diarrhoea 12.7% vs 0.7%.
RCTn = 812
Schmid et al. Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial